Archives
-
Annular Sector Microneedles for Glaucoma Therapy
2026-09-10
Huang and colleagues developed an annular sector-shaped microneedle patch to deliver an Nmnat1 gene formulation and nicotinamide directly to the trabecular meshwork. The combined treatment improved mitochondrial support in human trabecular meshwork cells and reduced intraocular pressure and fibrosis in a dexamethasone-induced mouse model, providing a localized strategy for addressing glaucoma-associated tissue dysfunction.
-
Cy7 NHS ester: Practical Labeling and QC Guide
2026-09-10
Cy7 NHS ester (SKU A8109) is a water-soluble, sulfonated near-infrared dye for labeling accessible amino groups on proteins, peptides, and related biomolecules. It is useful when aqueous handling and near-infrared fluorescent imaging are priorities, but this guide does not substitute for target-specific optimization or validation, and no directly matched paper evidence is used.
-
3-Bromopyruvate Overcomes Cetuximab Resistance in CRC
2026-09-09
Mu and colleagues show that combining 3-bromopyruvate with cetuximab can restore drug sensitivity in colorectal cancer models with intrinsic or acquired cetuximab resistance. The study links this effect to FOXO3a-dependent activation of autophagy, ferroptosis, and apoptosis, providing a mechanistic framework for investigating resistant tumors.
-
Oteseconazole (VT-1161) Candida Assay Workflows
2026-09-09
Oteseconazole (VT-1161) combines potent Candida activity with selective fungal CYP51 targeting, making it a useful benchmark for susceptibility, resistance, and mechanism-focused studies. This workflow guide connects concentration planning, controls, and troubleshooting to practical research use cases without confusing in vitro findings with clinical conclusions.
-
Nystatin (Fungicidin): Workflow & Assay Guide
2026-09-08
Nystatin (Fungicidin) combines a defined ergosterol-targeting mechanism with practical value in Candida susceptibility, adhesion, and membrane-integrity studies. This guide also shows how to use Nystatin as a specificity control in reovirus entry experiments without confusing antifungal activity with antiviral efficacy.
-
Intranasal Epinephrine in Dogs: PK and Heart Rate
2026-09-08
The reference study evaluated intranasal epinephrine as a rapid, needle-free alternative to intramuscular delivery in dogs, combining dose-ranging pharmacokinetics with heart-rate measurements. Its most important finding was that intranasal dosing produced rapid systemic exposure and comparable overall exposure at selected dose pairs, while producing smaller heart-rate increases than intramuscular administration.
-
Pemetrexed Workflows for Translational Cancer Research
2026-09-07
Build reproducible Pemetrexed assays that connect folate-pathway inhibition with DNA-repair phenotypes in tumor models. This workflow combines dose-response profiling, biomarker-aware controls, and practical troubleshooting for non-small cell lung carcinoma research and malignant mesothelioma models.
-
How p38α Inhibitors Tune Dephosphorylation
2026-09-07
A bioRxiv preprint reports that selected p38α MAP kinase inhibitors can both inhibit catalysis and accelerate WIP1-mediated removal of the activation-loop phosphate. Biochemical experiments and X-ray structures connect this dual action to an inhibitor-stabilized activation-loop conformation that exposes phospho-threonine, suggesting a route toward greater kinase-inhibitor specificity.
-
Ozone, Efferocytosis, and Neuropathic Pain
2026-09-05
A 2024 Frontiers in Immunology study identifies macrophage efferocytosis as a mechanistically actionable process in neuropathic pain. In a chronic constriction injury model, ozone enhanced AMPK/Gas6-MerTK signaling, increased apoptotic-cell clearance, elevated SOCS3, and reduced inflammatory mediators, linking defective corpse removal with pain hypersensitivity.
-
FAST for Food-Grade Nutraceutical Nanoparticles
2026-09-04
The 2026 reference study presents Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade route for forming stable nanoparticles from poorly soluble nutraceuticals. Its findings suggest that FAST can improve formulation stability and support scalable oral delivery, although full product-specific regulatory and bioavailability validation remains necessary.
-
FXR Phase Separation Clusters Coronavirus Organelles
2026-09-04
Li et al. (2024) identify fragile X–related proteins as host factors that organize β-coronavirus replication organelles through liquid–liquid phase separation. The study connects FXR condensates, double-membrane vesicle clustering, local translation, and SARS-CoV-2 replication, providing a mechanistic framework for interpreting replication-organelle architecture.
-
Vancomycin and the Gut–Immune Axis in AR Models
2026-09-03
Vancomycin is examined here as a controlled microbiome perturbation tool rather than only a conventional glycopeptide antibiotic. The article connects peptidoglycan precursor binding with allergic-rhinitis assay design, integrating microbial, metabolic, and immune readouts while defining the limits of current evidence.
-
25-Hydroxycholesterol Reprograms Immunosuppressive TAMs
2026-09-03
Xiao et al. identify CH25H and lysosomal 25-hydroxycholesterol as an immunometabolic checkpoint that connects cholesterol handling to AMPKα–STAT6 signaling in tumor-associated macrophages. The study also shows that targeting CH25H can increase T-cell activity and improve anti-tumor responses, including in combination with anti-PD-1 therapy.
-
DAPI Workflows for Nuclear Imaging and Viability
2026-09-02
DAPI Solution (1 mg/mL) supports high-contrast nuclear imaging, membrane-compromise readouts, and flow-based DNA staining in workflows ranging from fixed-cell microscopy to tumor-microenvironment studies. This guide connects practical staining decisions with the PAD4–H3cit–NETs findings reported in a recent cancer study, while clarifying what DAPI can—and cannot—prove about apoptosis or therapeutic response.
-
Thymoquinone C5035: Reliable Cell Assay Workflows
2026-09-02
A scenario-driven guide to using Thymoquinone (SKU C5035) in cell viability, proliferation, and cytotoxicity workflows. It connects formulation, dosing, controls, interpretation, and vendor selection with mechanistic and cardiotoxicity evidence.